Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 269

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety Outcomes of CAR T-Cell Therapies in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Who Received Prior Treatment with Mosunetuzumab

Adam Braun, Stephen J. Schuster, Loretta Nastoupil, Nancy L. Bartlett, Mazyar Shadman, Anita Kumar, Dimitrios Tzachanis, Dai Chihara, Mei Wu, Michael C. Wei, Shen Yin, Jing Qi Hao, Qian Zhu, Yong Mun, L. Elizabeth Budde

Blood (2024) 144 (Supplement 1): 6555.

https://doi.org/10.1182/blood-2024-198409

Published: 2024

Journal Articles

Prognostic Significance of Clinical Characteristics and Baseline PET-CT Metabolic Parameters in Patients with Marginal Zone Lymphoma

Imran A. Nizamuddin, Adeel Haq, Fei Wan, Marcus P. Watkins, Lauren Kelly Shea, Nancy L. Bartlett, Brad S. Kahl, Joyce Mhlanga, Neha Mehta-Shah

Blood (2024) 144 (Supplement 1): 6334.

https://doi.org/10.1182/blood-2024-204458

Published: 2024

Journal Articles

ALPHA3, a Pivotal Phase 2 Study of First-Line Consolidation with Cemacabtagene Ansegedleucel (Cema-Cel) in Patients with Large B-Cell Lymphoma and Minimal Residual Disease after Response to Standard Therapy

Blood (2024) 144 (Supplement 1): 3132.1.

https://doi.org/10.1182/blood-2024-194909

Published: 2024

Journal Articles

Trial in Progress - Alliance A051901 - Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed By Lenalidomide and Nivolumab Maintenance in Primary Central Nervous System Lymphoma (PCNSL)

Alvaro J Alencar, Olivia Bobek, Neha Mehta-Shah, Narendranath Epperla, Christine Lu-Emerson, Sarah C. Rutherford, Adam J. Olszewski, Thomas Ollila, Samuel Singer, Travis Dockter, Susan M. Geyer, Lori Rosenstein, Macarena De La Fuente, Eric D. Hsi, Shira N. Dinner, James L. Rubenstein, Nancy L. Bartlett, John P. Leonard

Blood (2024) 144 (Supplement 1): 4502.4.

https://doi.org/10.1182/blood-2024-209238

Published: 2024

Journal Articles

Mosunetuzumab Monotherapy Demonstrates Encouraging Activity and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed or Refractory Mantle Cell Lymphoma

L. Elizabeth Budde, Matthew Matasar, Laurie H. Sehn, Sarit E. Assouline, John Kuruvilla, Ian W. Flinn, Sung-Soo Yoon, Francesc Bosch, Daniel Greenwald, Norma C. Gutierrez, Dimitrios Tzachanis, Paula Marlton, Delaney McGuirt, Shen Yin, Michael C. Wei, Antonia Kwan, Samuel Tracy, Elicia Penuel, Nancy L. Bartlett

Blood (2024) 144 (Supplement 1): 1646.

https://doi.org/10.1182/blood-2024-197902

Published: 2024

Journal Articles

Trial in Progress - Alliance A052101: A Randomized Phase 3 Trial of Continuous Vs. Intermittent Maintenance Therapy with Zanubrutinib As Upfront Treatment in Older Patients with Mantle Cell Lymphoma

Anne W Beaven, Susan M. Geyer, Jonathon B. Cohen, Tycel Phillips, Travis Dockter, Priyanka A. Pophali, Gita Thanarajasingam, Gina L. Mazza, Alvaro J Alencar, Shira N. Dinner, Eric D. Hsi, Meng Welliver, Daniel Nikcevich, Brad S. Kahl, Jonathan W. Friedberg, Nancy L. Bartlett, John P. Leonard

Blood (2024) 144 (Supplement 1): 1661.3.

https://doi.org/10.1182/blood-2024-207372

Published: 2024

Journal Articles

Mosunetuzumab Plus Polatuzumab Vedotin Induces Early Complete Responses in Previously Untreated High Tumor Burden Follicular Lymphoma

David A Russler-Germain, Fei Wan, Emily R. King, Chaz Moreno, Michelle Becker-Hapak, Patrick Pence, Joseph Rueve, Sushanth A Pureti, Dilan A. Patel, Brad S. Kahl, Neha Mehta-Shah, Todd A Fehniger, Nancy L. Bartlett

Blood (2024) 144 (Supplement 1): 4414.

https://doi.org/10.1182/blood-2024-202085

Published: 2024

Journal Articles

Long-Term Follow-up of Bendamustine/Rituximab - Rituximab/Cytarabine (BR/RC) Induction Therapy for Previously Untreated Transplant-Eligible Patients with Mantle Cell Lymphoma (MCL)

Blood (2024) 144 (Supplement 1): 4409.

https://doi.org/10.1182/blood-2024-198687

Published: 2024

Journal Articles

Disrupting IL10 Signaling Overcomes Compound Copy Number Variation-Driven Clinical Resistance to CDK4/6 and BTK Inhibition in Mantle Cell Lymphoma

Maurizio Di Liberto, Yang Hu, Xiangao Huang, Giorgio Inghirami, Kevin Wang, Christina Y. Lee, Kami J. Maddocks, Kristie A. Blum, Jia Ruan, John P. Leonard, Nancy L. Bartlett, Peter Martin, Olivier Elemento, Selina Chen-Kiang

Blood (2024) 144 (Supplement 1): 831.

https://doi.org/10.1182/blood-2024-209415

Published: 2024

Journal Articles

Updated Analysis of Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Nonbulky, Early-Stage Classical Hodgkin Lymphoma

Blood (2024) 144 (Supplement 1): 460.

https://doi.org/10.1182/blood-2024-200992

Published: 2024

Journal Articles

Pembrolizumab Gemcitabine Vinorelbine and Liposomal Doxorubicin (P-GVD) for Classical Hodgkin Lymphoma (CHL) in the Real-World Setting

Blood (2024) 144 (Supplement 1): 4431.

https://doi.org/10.1182/blood-2024-200719

Published: 2024

Journal Articles

Englumafusp Alfa (CD19-4-1BBL) Combined with Glofitamab Is Safe and Efficacious in Patients with r/r B-NHL: Extended Follow up Analysis of the Dose-Escalation Part of Phase 1 Trial BP41072

Blood (2024) 144 (Supplement 1): 990.

https://doi.org/10.1182/blood-2024-200096

Published: 2024

Journal Articles

Phase I Results of Acalabrutinib in Combination with Durvalumab in Primary Central Nervous System Lymphoma: Safety, Efficacy, and Central Nervous System Penetration

Imran A. Nizamuddin, Narendranath Epperla, Mary-Kate Malacek, Brad S. Kahl, Fei Wan, Anne Fischer, Chaz Moreno, Emily R. King, Anna Krivenko, Nancy L. Bartlett, Neha Mehta-Shah

Blood (2024) 144 (Supplement 1): 985.

https://doi.org/10.1182/blood-2024-204521

Published: 2024

Journal Articles

Glofitamab Induces High Response Rates and Durable Remissions in Patients (Pts) with Heavily Pretreated Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL), Including Those with a Poor Prognosis: Subgroup Results from a Phase I/II Study

Blood (2024) 144 (Supplement 1): 1631.

https://doi.org/10.1182/blood-2024-200018

Published: 2024

Journal Articles

Addition of Monoclonal Protein to MALT-IPI Improved Identification of MALT Patients at High Risk of Progression with Current First-Line Therapies

Narendranath Epperla, Natalie Grover, Pallawi Torka, Reem Karmali, Kaitlin Annunzio, Marcus P. Watkins, Andrea Carolina Anampa-Guzmán, Heather Reves, Montreh Tavakkoli, Beth Christian, Colin Thomas, Stefan K. Barta, Praveen Ramakrishnan Geethakumari, Geoffrey Shouse, Nancy L. Bartlett, Adam J. Olszewski

Blood (2024) 144 (Supplement 1): 398.

https://doi.org/10.1182/blood-2024-202697

Published: 2024

Journal Articles

Fixed-Duration Glofitamab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed or Refractory Large B-Cell Lymphoma: 3-Year Follow-up from a Pivotal Phase II Study

Blood (2024) 144 (Supplement 1): 865.

https://doi.org/10.1182/blood-2024-194333

Published: 2024

Journal Articles

Primary Results of the Health-Related Quality of Life (HRQoL) and Tolerability Assessments from the Phase I/II NP30179 Study of Glofitamab Monotherapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Emmanuel Bachy, Peter Trask, Franck Morschhauser, Paolo Corradini, Shang-Ju Wu, Nancy L. Bartlett, Estefania Mulvihill, Fabiola Bene Tchaleu, Linda Lundberg, Carmelo Carlo-Stella

Blood (2024) 144 (Supplement 1): 1726.

https://doi.org/10.1182/blood-2024-194337

Published: 2024

Journal Articles

Subcutaneous Mosunetuzumab Leads to High Rates of Durable Responses, Low Rates of Cytokine Release Syndrome, and Non-Inferior Exposure Compared with Intravenous Administration in Patients with Relapsed/Refractory Follicular Lymphoma: Primary Analysis of a Pivotal Phase II

Blood (2024) 144 (Supplement 1): 1645.

https://doi.org/10.1182/blood-2024-194612

Published: 2024

Journal Articles

Mosunetuzumab Continues to Demonstrate Clinically Meaningful Outcomes in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies Including Those with a History of POD24: 4-Year Follow-up of a Pivotal Phase II Study

Blood (2024) 144 (Supplement 1): 4407.

https://doi.org/10.1182/blood-2024-197897

Published: 2024

Journal Articles

Durability of Complete Responses in Patients from the ECHELON-3 Study

Blood (2024) 144 (Supplement 1): 3101.

https://doi.org/10.1182/blood-2024-194158

Published: 2024

NARROW

Efficacy and Safety Outcomes of CAR T-Cell Therapies in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Who Received Prior Treatment with Mosunetuzumab

Prognostic Significance of Clinical Characteristics and Baseline PET-CT Metabolic Parameters in Patients with Marginal Zone Lymphoma

ALPHA3, a Pivotal Phase 2 Study of First-Line Consolidation with Cemacabtagene Ansegedleucel (Cema-Cel) in Patients with Large B-Cell Lymphoma and Minimal Residual Disease after Response to Standard Therapy

Trial in Progress - Alliance A051901 - Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed By Lenalidomide and Nivolumab Maintenance in Primary Central Nervous System Lymphoma (PCNSL)

Mosunetuzumab Monotherapy Demonstrates Encouraging Activity and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed or Refractory Mantle Cell Lymphoma

Trial in Progress - Alliance A052101: A Randomized Phase 3 Trial of Continuous Vs. Intermittent Maintenance Therapy with Zanubrutinib As Upfront Treatment in Older Patients with Mantle Cell Lymphoma

Mosunetuzumab Plus Polatuzumab Vedotin Induces Early Complete Responses in Previously Untreated High Tumor Burden Follicular Lymphoma

Long-Term Follow-up of Bendamustine/Rituximab - Rituximab/Cytarabine (BR/RC) Induction Therapy for Previously Untreated Transplant-Eligible Patients with Mantle Cell Lymphoma (MCL)

Disrupting IL10 Signaling Overcomes Compound Copy Number Variation-Driven Clinical Resistance to CDK4/6 and BTK Inhibition in Mantle Cell Lymphoma

Updated Analysis of Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Nonbulky, Early-Stage Classical Hodgkin Lymphoma

Pembrolizumab Gemcitabine Vinorelbine and Liposomal Doxorubicin (P-GVD) for Classical Hodgkin Lymphoma (CHL) in the Real-World Setting

Englumafusp Alfa (CD19-4-1BBL) Combined with Glofitamab Is Safe and Efficacious in Patients with r/r B-NHL: Extended Follow up Analysis of the Dose-Escalation Part of Phase 1 Trial BP41072

Phase I Results of Acalabrutinib in Combination with Durvalumab in Primary Central Nervous System Lymphoma: Safety, Efficacy, and Central Nervous System Penetration

Glofitamab Induces High Response Rates and Durable Remissions in Patients (Pts) with Heavily Pretreated Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL), Including Those with a Poor Prognosis: Subgroup Results from a Phase I/II Study

Addition of Monoclonal Protein to MALT-IPI Improved Identification of MALT Patients at High Risk of Progression with Current First-Line Therapies

Fixed-Duration Glofitamab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed or Refractory Large B-Cell Lymphoma: 3-Year Follow-up from a Pivotal Phase II Study

Primary Results of the Health-Related Quality of Life (HRQoL) and Tolerability Assessments from the Phase I/II NP30179 Study of Glofitamab Monotherapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Subcutaneous Mosunetuzumab Leads to High Rates of Durable Responses, Low Rates of Cytokine Release Syndrome, and Non-Inferior Exposure Compared with Intravenous Administration in Patients with Relapsed/Refractory Follicular Lymphoma: Primary Analysis of a Pivotal Phase II

Mosunetuzumab Continues to Demonstrate Clinically Meaningful Outcomes in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies Including Those with a History of POD24: 4-Year Follow-up of a Pivotal Phase II Study

Durability of Complete Responses in Patients from the ECHELON-3 Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only